NCT00670189View on ClinicalTrials.gov

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions
Hedgehog PathwaySmoothenedBasal Cell Carcinoma (BCC)Basal Cell Nevoid Syndrome (BCNS)
Interventions
DRUG

BMS-833923 (XL139)

Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit

Trial Locations (3)

55905

Mayo Clinic Rochester, Rochester

78229

Southwest Texas Addiction Research And Tech (Start) Center, San Antonio

M5G 2M9

Local Institution, Toronto

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY